FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:1683-1685 April 15, 2004 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Spivak, J. Related Article by Landolfi, R. PubMed Citation

To the Editor: The European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) trial, as reported by Landolfi et al. (Jan. 8 issue),¹ does not entirely clarify the role of aspirin in the treatment of polycythemia vera. There were more smokers in the placebo group than in the aspirin group. The treatment of polycythemia vera has clearly been suboptimal in most patients. In the study by Landolfi et al., the hematocrit was higher than 48 percent in 25 percent of the patients, and 25 percent had platelet counts that were higher than 460,000 per cubic millimeter.

Carol Alliot, M.D.
General . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.